首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1562318

北美人疫苗佐劑市場預測至 2030 年 - 區域分析 - 按類型、應用（流感、肝炎、人類乳突病毒等）和最終用戶

North America Human Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Type, Application (Influenza, Hepatitis, Human papilloma virus, and Others), and End User

出版日期: 2024年07月04日 | 出版商:

The Insight Partners | 英文 109 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2022年北美人疫苗佐劑市場估值為65,608萬美元，預計2030年將達到18,3801萬美元；預計2022年至2030年複合年成長率為13.7%。

慢性病盛行率上升推動北美人用疫苗佐劑市場

慢性病盛行率的上升推動了對疫苗佐劑的需求。疫苗中添加佐劑以增強功效和身體的免疫反應。它們透過刺激更強、更持久的免疫反應來幫助提高疫苗的有效性。隨著預防和管理慢性病的疫苗需求持續成長，佐劑的需求也隨之增加。心血管疾病、癌症、糖尿病和呼吸系統疾病等慢性病在全球呈現上升趨勢。據世界衛生組織稱，與非傳染性疾病相關的死亡人數最多的是心血管疾病，每年造成 1700 萬人死亡，其次是癌症、慢性呼吸道疾病和糖尿病（包括與腎臟相關的死亡）。此外，根據世界心臟聯盟的數據，高膽固醇每年導致 440 萬人死亡，約 24% 的心血管相關死亡可歸因於高低密度脂蛋白 (LDL) 膽固醇。因此，慢性病負擔的增加導致對能夠預防或控制這些疾病的疫苗的需求不斷成長。老年人口的增加也增加了對疫苗的需求。 NCBI 2023 年 1 月發布的一項研究顯示，到 2050 年，美國 50 歲及以上人口將達到 22113 萬人，較 2020 年的 13725 萬人快速成長。，預計這一數字將從2020 年的7152 萬人增加到2050 年的1.4266 萬人，成長99.5%。是也在增加。肝炎疫苗中的佐劑旨在引發強大而持久的免疫力，特別是對標準疫苗配方反應不佳的人群，例如患有潛在疾病或與年齡相關的免疫衰老的人群。據世界衛生組織稱，全世界有超過 3.5 億人患有乙型或丙型肝炎。根據世界衛生組織的一項研究，到 2030 年，低收入和中等收入國家估計可透過疫苗接種預防 450 萬人因肝炎而過早死亡。因此，慢性病盛行率的增加推動了北美人類疫苗佐劑市場的成長。

北美人用疫苗佐劑市場概況

美國在北美人類疫苗佐劑市場中佔有重要佔有率。該國的市場成長主要歸因於政府醫療保健支出的增加以及對新型疫苗配方的需求激增，以更有效地治療傳染病。根據美國醫療保險和醫療補助服務中心的數據，2021 年美國國民醫療保健支出成長 2.7%，達到 4.3 兆美元，即人均 12,914 美元。醫療衛生支出佔全國GDP的18.3%。美國衛生與公眾服務部預計，2019-2028年國家衛生支出將以年均5.4%的速度成長，到2028年將達到6.2兆美元。刺激了對人用疫苗佐劑的需求。根據 2020 年 7 月發布的全球疾病負擔研究的新發現，美國的非傳染性疾病和傳染病負擔巨大且不斷增加。據約翰霍普金斯大學稱，近二十年來，美國SARS、萊姆病、登革熱、西尼羅河病毒、寨卡病毒等疾病感染病例迅速增加。此外，同一消息來源也證實，瘧疾、結核病、霍亂、百日咳、流感、肺炎球菌疾病和淋病等重新出現的疾病的發生率增加。同樣，根據美國疾病管制與預防中心 (CDC) 的數據，2010 年至 2022 年間，流感每年導致 100,000 至 710,000 人住院治療，4,900 至 52,000 人死亡。有1.405 億15 歲及以上女性面臨HPV 相關子宮頸癌的風險。在美國普通人群中，預計有近 3.9% 的女性在特定時間攜帶子宮頸 HPV16/18 感染，71.2% 的浸潤性子宮頸癌歸因於 HPV 16 或 18。方面的努力，推動了美國北美人類疫苗佐劑市場的成長。美國政府努力為在該國開發和商業化藥品和保健產品創造有利的環境。該國擁有多個潛在的製藥和醫療器材市場參與者，包括輝瑞、諾華、波士頓科學、Integra LifeSciences、安進和雅培，其製藥和醫療器材行業創新擁有各種專利。因此，各製藥巨頭藥物開發活動的增加提振了美國的北美人疫苗佐劑市場。

北美人類疫苗佐劑市場收入及 2030 年預測（百萬美元）

北美人用疫苗佐劑市場區隔

北美人疫苗佐劑市場按類型、應用、最終用戶和國家分類。

依類型，北美人疫苗佐劑市場分為顆粒佐劑、乳液佐劑、組合佐劑等。 2022 年，顆粒助劑領域佔最大的市場佔有率。

從應用來看，北美人疫苗佐劑市場分為流感、肝炎、人類乳突病毒（HPV）等。 2022 年，流感細分市場佔據最大市場。

依最終用戶分類，北美人疫苗佐劑市場分為製藥和生技公司、CMO 和 CRO 等。 2022 年，製藥和生物技術公司細分市場佔據最大市場佔有率。

依國家分類，北美人疫苗佐劑市場分為美國、加拿大和墨西哥。 2022年，美國在北美人類疫苗佐劑市場佔有率中佔據主導地位。

Creative Biolabs Inc、Croda International Plc、CSL Ltd、Dynavax Technologies Corp、Hawaii Biotech Inc、Novartis AG、Novavax Inc、Phibro Animal Health Corp、Seppic SA 和 SPI Pharma Inc 是北美人類疫苗佐劑領域的領先公司市場。

The rising prevalence of chronic diseases is fueling the demand for vaccine adjuvants. Adjuvants are added to vaccines to enhance the efficacy and body's immune response. They help improve the effectiveness of vaccines by stimulating a stronger and longer-lasting immune response. As the demand for vaccines to prevent and manage chronic diseases continues to grow, the demand for adjuvants also increases. Chronic diseases such as cardiovascular diseases, cancer, diabetes, and respiratory diseases are rising globally. According to the World Health Organization, the most noncommunicable disease-related deaths are cardiovascular diseases, accounting for ?17 million people each year, followed by cancers, chronic respiratory diseases, and diabetes (including deaths associated with the kidney). Furthermore, according to the World Heart Federation, high cholesterol causes 4.4 million deaths yearly, and ?24% of cardiovascular-related deaths are attributable to high low-density lipoprotein (LDL) cholesterol. Thus, the increasing burden of chronic diseases has led to a growing demand for vaccines that can prevent or manage these conditions. The rising geriatric population is also bolstering the demand for vaccines. As per a study published in January 2023 by NCBI, in the US, the number of people aged 50 years and older will reach 221.13 million by 2050, a rapid increase from 137.25 million in 2020. People aged 50 and above are expected to suffer from at least one chronic disease, and the figure is projected to rise by 99.5% from 71.52 million in 2020 to 142.66 million by 2050. Also, it is projected that ~14 million people are likely to suffer from multimorbidity by 2050 The prevalence of hepatitis is also increasing. Adjuvants in hepatitis vaccines aim to elicit robust and durable immunity, particularly in populations with suboptimal responses to standard vaccine formulations, such as those with underlying medical conditions or age-related immune senescence. According to the WHO, more than 350 million people worldwide live with hepatitis B or C. Among all types of hepatitis, several are preventable through vaccination. As per a study by WHO, an estimated 4.5 million premature deaths due to hepatitis could be prevented in low- and middle-income countries by 2030 through vaccination. Thus, the increasing prevalence of chronic diseases drives the growth of the North America human vaccine adjuvants market.

North America Human Vaccine Adjuvants Market Overview

The US holds a significant share of the North America human vaccine adjuvants market in North America. The market growth in this country is mainly ascribed to rising government spending on healthcare and a surging demand for novel vaccine formulations to treat infectious diseases more efficiently. According to the US Centers for Medicare & Medicaid Services, national healthcare expenditures in the US increased by 2.7% in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Health spending accounted for 18.3% of the nation's GDP. As per the US Department of Health & Human Services, national health spending is expected to grow at an annual rate of 5.4% from 2019-2028, reaching US$ 6.2 trillion by 2028. The rising health expenditure may lead to a rise in funds allocation for the research and development of vaccines, fueling the demand for human vaccine adjuvants. According to new findings derived from the Global Burden of Disease study published in July 2020, there is a large and increasing burden of noncommunicable and infectious diseases in the US. According to Johns Hopkins University, the cases of diseases such as SARS, Lyme disease, dengue fever, West Nile virus, and Zika virus infection have increased rapidly in the last two decades in the US. Also, the same source affirmed an increase in the incidence of re-emerging diseases such as malaria, tuberculosis, cholera, pertussis, influenza, pneumococcal disease, and gonorrhea. Similarly, according to the Centers for Disease Control and Prevention (CDC), flu has resulted in 100,000 to 710,000 hospitalizations and 4,900 to 52,000 deaths annually between 2010 and 2022. According to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, the US has a population of 140.5 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Nearly 3.9% of women in the US in the general population are projected to harbor cervical HPV16/18 infection at a given time, and 71.2% of invasive cervical cancers are attributed to HPVs 16 or 18. Thus, a rise in the incidences of various infections and re-emerging diseases boosts companies' efforts in vaccine development, fueling the North America human vaccine adjuvants market growth in the US. The US government strives to create a conducive environment for developing and commercializing pharmaceutical and healthcare products in the country. The country has several potential pharmaceutical and medical device market players, including Pfizer, Novartis, Boston Scientific, Integra LifeSciences, Amgen, and Abbott, with various patents for their pharmaceutical and medical device industry innovations. Thus, an increase in drug development activities by various pharmaceutical giants bolsters the North America human vaccine adjuvants market in the US.

North America Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

North America Human Vaccine Adjuvants Market Segmentation

The North America human vaccine adjuvants market is categorized into type, application, end user, and country.

Based on type, the North America human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.

In terms of application, the North America human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held the largest market share in 2022.

By end user, the North America human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.

By country, the North America human vaccine adjuvants market is segmented into the US, Canada, and Mexico. The US dominated the North America human vaccine adjuvants market share in 2022.

Creative Biolabs Inc, Croda International Plc, CSL Ltd, Dynavax Technologies Corp, Hawaii Biotech Inc, Novartis AG, Novavax Inc, Phibro Animal Health Corp, Seppic SA, and SPI Pharma Inc are among the leading companies operating in the North America human vaccine adjuvants market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Human Vaccine Adjuvants Market - Key Market Dynamics

4.1 North America Human Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Chronic Diseases
- 4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
- 4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
- 4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
- 4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:

5. Human Vaccine Adjuvants Market - North America Market Analysis

5.1 North America Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030
5.2 North America Human Vaccine Adjuvants Market Forecast Analysis

6. North America Human Vaccine Adjuvants Market Analysis - by Type

6.1 Particulate Adjuvant
- 6.1.1 Overview
- 6.1.2 Particulate Adjuvant: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
- 6.2.1 Overview
- 6.2.2 Emulsion Adjuvant: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
- 6.3.1 Overview
- 6.3.2 Combination Adjuvant: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Others
- 6.4.1 Overview
- 6.4.2 Others: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Human Vaccine Adjuvants Market Analysis - by Application

7.1 Influenza
- 7.1.1 Overview
- 7.1.2 Influenza: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
- 7.2.1 Overview
- 7.2.2 Hepatitis: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Human papilloma virus (HPV)
- 7.3.1 Overview
- 7.3.2 Human papilloma virus (HPV): North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Human Vaccine Adjuvants Market Analysis - by End User

8.1 Pharmaceutical and Biotechnology Companies
- 8.1.1 Overview
- 8.1.2 Pharmaceutical and Biotechnology Companies: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
- 8.2.1 Overview
- 8.2.2 CMOs and CROs: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Human Vaccine Adjuvants Market - Country Analysis

9.1 North America
- 9.1.1 North America Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  - 9.1.1.1 US Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.1 US Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.1.2 US Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.1.3 US Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.2 Canada Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.1 Canada Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.2.2 Canada Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.2.3 Canada Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.3 Mexico Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.1 Mexico Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.3.2 Mexico Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.3.3 Mexico Human Vaccine Adjuvants Market Breakdown, by End User

10. Industry Landscape

10.1 Overview

11. Company Profiles

11.1 Novartis AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Dynavax Technologies Corp
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 CSL Ltd
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Seppic SA
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 SPI Pharma Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Hawaii Biotech Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Croda International Plc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Novavax Inc
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Phibro Animal Health Corp
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 Creative Biolabs Inc
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. North America Human Vaccine Adjuvants Market Segmentation
Table 2. North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 4. North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 5. North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
Table 6. US Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 7. US Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 8. US Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 9. Canada Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 10. Canada Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 11. Canada Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 12. Mexico Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 13. Mexico Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 14. Mexico Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 15. Recent Growth Strategies in the Human Vaccine Adjuvants Market
Table 16. Glossary of Terms, Human Vaccine Adjuvants Market

List Of Figures

Figure 1. North America Human Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. North America Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
Figure 4. North America Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
Figure 5. Particulate Adjuvant: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Combination Adjuvant: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. North America Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)
Figure 10. Influenza: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Human papilloma virus (HPV): North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)
Figure 15. Pharmaceutical and Biotechnology Companies: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. CMOs and CROs: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: North America Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. North America Human Vaccine Adjuvants Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
Figure 19. North America Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 20. US Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 21. Canada Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 22. Mexico Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)